Sugi Predict

Sugi Predict / Compounds / SCHEMBL9904651

SCHEMBL9904651

SCHEMBL9904651

COC(=O)c1ccc2c(c1)c(I)nn2C1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ DGAT2 Q96PD7 1/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ RXRG P48443 1/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ MAPT P10636 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ SCARB1 Q8WTV0 1/20 0.38
▸ ATR Q13535 1/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ NQO2 P16083 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159627 1.00 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1
SCHEMBL18816227 0.91 DGAT2 (0.45) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1
SCHEMBL27032319 0.89 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2NPSR1MAPK1RAB9A
SCHEMBL10324149 0.88 DGAT2 (0.40) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1
SCHEMBL30159592 0.88 DGAT2 (0.40) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1
SCHEMBL29444527 0.88 HCAR3 (0.43) ALDH1A1DGAT2RAB9AHPGDRXRA
SCHEMBL9904464 0.88 HCAR3 (0.43) ALDH1A1DGAT2RAB9AHPGDRXRA
SCHEMBL18548025 0.87 DGAT2 (0.40) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1
SCHEMBL30159688 0.86 DGAT2 (0.39) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1
SCHEMBL10324566 0.86 DGAT2 (0.39) ALDH1A1SMN1; SMN2ATMNPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042883-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2025-02-06 — — US disclosed
CN-113853371-B GLP-1R agonists and uses thereof 上海齐鲁锐格医药研发有限公司 2024-05-03 — — CN disclosed
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-09-07 — — US disclosed
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-09-07 — — US disclosed
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-09-07 — — US disclosed
US-11591321-B2 GLP-1R agonists and uses thereof QILU REGOR THERAPEUTICS INC. (CN) 2023-02-28 — — US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 — — US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 — — US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 — — CN disclosed
EP-4076440-A1 INHIBITORS OF ENL/AF9 YEATS The Rockefeller University (US) 2022-10-26 — — EP disclosed
US-10618897-B2 Spiroindolinones as DDR1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-04-14 — — US disclosed
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-03-07 — — US disclosed
EP-3414247-A1 SPIROINDOLINONES AS DDR1 INHIBITORS H. Hoffnabb-La Roche Ag (CH) 2018-12-19 — — EP disclosed
WO-2017137334-A1 SPIROINDOLINONES AS DDR1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-08-17 — — WO disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 — — US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 — — EP disclosed
WO-2012095781-A1 INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-07-19 — — WO disclosed
WO-2012095781-A1 INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-07-19 — — WO disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11591321-B2 GLP-1R agonists and uses thereof GLP1R, GPR119, GIPR ALDH1A1 778/4885SMN1; SMN2 3524/4885ATM 3898/4885
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 ALDH1A1 2425/4885SMN1; SMN2 4608/4885ATM 1915/4885
US-10618897-B2 Spiroindolinones as DDR1 inhibitors DDR1, DDR2, DDRGK1 ALDH1A1 1199/4885SMN1; SMN2 949/4885ATM 5/4885
US-20190071444-A1 SPIROINDOLINONES AS DDR1 INHIBITORS DDR1, DDR2, DDRGK1 ALDH1A1 1199/4885SMN1; SMN2 949/4885ATM 5/4885
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 ALDH1A1 502/4885SMN1; SMN2 4085/4885ATM 1088/4885
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, GIPR ALDH1A1 626/4885SMN1; SMN2 3406/4885ATM 3954/4885
US-20250042883-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, GIPR ALDH1A1 626/4885SMN1; SMN2 3406/4885ATM 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.